Adicet Bio, Inc.
About Adicet Bio, Inc.
Adicet Bio, Inc. is a privately held, pre-clinical stage biotechnology company developing novel universal immune cell therapies based on gamma delta T cells engineered with Chimeric Antigen Receptors. Adicet is also focused on identifying and validating cancer specific targets directed to the intracellular proteome and then generating T Cell Receptor-like monoclonal antibodies (TCRLs) directed to these cancer-specific peptide targets presented by MHC Class I complexes. These TCRLs are being used to arm T cells or as T cell engagers in solid tumors. In August 2016, Adicet entered into a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop next-generation engineered immune-cell therapeutics using Adicet's gamma delta T cell allogeneic platform technology.
For more information, please visit our website at http://www.adicetbio.com.
144 articles about Adicet Bio, Inc.
-
Adicet Bio to Participate in 2024 Canaccord Genuity Horizons in Oncology Virtual Conference
4/8/2024
Adicet Bio, Inc. today announced that Chen Schor, President and Chief Executive Officer will participate in a panel at the Canaccord Genuity Horizons in Oncology Virtual Conference being held April 15, 2024.
-
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - March 28, 2024
3/28/2024
Adicet Bio, Inc., a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, announced it granted an inducement award on March 28, 2024.
-
Adicet Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress
3/19/2024
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the fourth quarter and year ended December 31, 2023.
-
Adicet Bio to Participate in a Fireside Chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
3/11/2024
Adicet Bio, Inc. announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference being held March 26, 2024.
-
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - March 01, 2024
3/1/2024
Adicet Bio, Inc., a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, announced it granted an inducement award on February 29, 2024.
-
Adicet Bio to Participate in a Fireside Chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
2/5/2024
Adicet Bio, Inc. (Nasdaq: ACET) today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference being held from February 7-8, 2024 in New York.
-
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - Jan 31, 2024
1/31/2024
Adicet Bio, Inc., a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, announced it granted an inducement award on January 31, 2024.
-
Adicet Bio, Inc. Announces Closing of $98 Million Public Follow-On Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
1/25/2024
Adicet Bio, Inc. announced the closing of its previously announced underwritten public offering of 32,379,667 shares of its common stock, which includes 5,325,000 shares sold and issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock, and, in lieu of common stock to certain investors, pre-funded warrants to purchase 8,445,333 shares of common stock.
-
Adicet Bio, Inc. Announces Pricing of Public Offering - Jan 23, 2024
1/23/2024
Adicet Bio, Inc. announced the pricing of an underwritten public offering of 27,054,667 shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 8,445,333 shares of common stock.
-
Adicet Bio, Inc. Announces Proposed Public Offering - Jan 22, 2024
1/22/2024
Adicet Bio, Inc. announced that it has commenced an underwritten public offering of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock.
-
Adicet Provides Corporate Update and Highlights Strategic Priorities for 2024
1/4/2024
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and autoimmune diseases, today provided corporate updates and highlighted upcoming priorities for its pipeline programs in 2024.
-
Adicet Bio to Host Conference Call to Provide Updates on its Clinical Pipeline and Corporate Outlook
1/3/2024
Adicet Bio, Inc. (Nasdaq: ACET) today announced that the Company will host a conference call and webcast presentation on Thursday, January 4, 2024 at 8:00am ET to provide an update on its clinical pipeline and corporate outlook.
-
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - December 29, 2023
12/29/2023
Adicet Bio, Inc., a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, announced it granted an inducement award on December 29, 2023.
-
Adicet Bio Highlights ADI-001 Expansion, Persistence and Pharmacodynamic Profile from Ongoing Phase 1 Study at the 65th American Society of Hematology (ASH) Annual Meeting
12/10/2023
Adicet Bio, Inc. announced that an abstract outlining PK and PD profiling data from the Company’s ongoing Phase 1 study of ADI-001 for the potential treatment of relapsed or refractory aggressive B-cell NHL was made available as part of the 65th ASH Annual Meeting, being held December 9-12, 2023 in San Diego, California.
-
Adicet Reports Third Quarter 2023 Financial Results and Provides Business Updates
11/8/2023
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today reported financial results and operational highlights for the third quarter ended September 30, 2023.
-
Adicet Bio to Present at the 2023 Jefferies London Healthcare Conference
11/7/2023
Adicet Bio, Inc. announced that Chen Schor, President and Chief Executive Officer, will present at the 2023 Jefferies London Healthcare Conference being held from November 14-16, 2023 in London.
-
Adicet Bio Announces Poster Presentation Highlighting ADI-001 Data at the 65th American Society of Hematology (ASH) Annual Meeting
11/2/2023
Adicet Bio, Inc. announced the acceptance of a poster presentation at the upcoming 65th American Society of Hematology Annual Meeting to be held in San Diego, CA from December 9-12, 2023.
-
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - October 31, 2023
10/31/2023
Adicet Bio, Inc., a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, announced it granted an inducement award on October 31, 2023.
-
Adicet Bio Announces Poster Presentation at the Upcoming 2023 Molecular Targets and Cancer Therapeutics Conference
10/4/2023
Adicet Bio, Inc. (Nasdaq: ACET) today announced a poster presentation at the upcoming 2023 International Conference on Molecular Targets and Cancer Therapeutics hosted by the American Association for Cancer Research, the National Cancer Institute, and the European Organisation for Research and Treatment of Cancer to be held in Boston from October 11-15, 2023.
-
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - September 29, 2023
9/29/2023
Adicet Bio, Inc., a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, announced it granted inducement awards on September 29, 2023.